We are live on
!
Find out more
ACM
Athyrium Capital Management Portfolio holdings
AUM
$8.69M
1-Year Est. Return
34.58%
This Fund
S&P 500
This Quarter
Est. Return
-1.01%
1 Year Est. Return
-34.58%
3 Year Est. Return
-25.1%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$72.8M
AUM Growth
+$3.96M
(+5.8%)
Cap. Flow
-$49.2M
Cap. Flow
% of AUM
-67.59%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
3
New
–
Increased
–
Reduced
1
Closed
–
Top Buys
No buys this quarter
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Puma Biotechnology
PBYI
|
+$2.88M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 25.67% |
Similar funds
BGC
RVM
JDR
DA
KIM
RJTCONH
HSC
HVM
Athyrium Capital Management's Q1 2024 Portfolio in Review
As of Q1 2024, Athyrium Capital Management held 3 positions worth $72.8M, up 5.8% from $68.8M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Athyrium Capital Management withdrew a net $49.2M in Q1 2024, reducing 1 holding. Its largest reduction was Puma Biotechnology, cutting an estimated $2.88M.
By sector, the portfolio is most concentrated in Healthcare at 26% of assets, down from 33% a quarter earlier.
- Athyrium Capital Management's biggest Q1 2024 reduction was Puma Biotechnology, cutting an estimated $2.88M.
- Athyrium Capital Management's ten largest holdings make up 100% of its $72.8M portfolio in Q1 2024.
- Athyrium Capital Management opened 0 new positions and closed 0 in Q1 2024.
- Athyrium Capital Management's portfolio value rose 5.8% quarter-over-quarter to $72.8M.
Based on Athyrium Capital Management's 13F filing for Q1 2024, filed 16 May 2024.